Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aegerion gains on Juxtapid update

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) jumped $14.73 (31%) to $61.70 on Thursday after the company

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE